[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640684":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":94,"collaborators":23,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":23,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":23,"enrollmentInfo":105,"targetDuration":23,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":23,"overallStatus":37,"whyStopped":23,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-4884 Dose Escalation Schedule A","EXPERIMENTAL","Participants will receive MK-4884 at varying dose levels until any of the criteria for discontinuation of the study intervention are met.",[13],"Drug: MK-4884",{"label":15,"type":10,"description":11,"interventionNames":16},"MK-4884 Dose Escalation Schedule B",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","MK-4884","Oral Administration",[9,15],null,[25],{"name":26,"affiliation":5,"role":27},"Medical Director","STUDY_DIRECTOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":23,"email":33},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[35,53,67,79],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"NEXT Oncology ( Site 0151)","RECRUITING","San Antonio","Texas","78229","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-98.49363,29.42412,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":52,"phoneExt":23,"email":23},"Study Coordinator","210-568-4397",{"facility":54,"status":37,"city":55,"state":23,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Rambam Health Care Campus ( Site 0051)","Haifa","3109601","Israel","IL",{"type":44,"coordinates":60},[61,62],34.99928,32.81303,{"lat":62,"lon":61},[65],{"name":51,"role":31,"phone":66,"phoneExt":23,"email":23},"+97247776731",{"facility":68,"status":37,"city":69,"state":23,"zip":70,"country":57,"countryCode":58,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Rabin Medical Center ( Site 0053)","Petah Tikva","4941492",{"type":44,"coordinates":72},[73,74],34.88747,32.08707,{"lat":74,"lon":73},[77],{"name":51,"role":31,"phone":78,"phoneExt":23,"email":23},"+97239377377",{"facility":80,"status":37,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"National Cancer Center Hospital ( Site 0201)","Chūō","Tokyo","104-0045","Japan","JP",{"type":44,"coordinates":87},[88,89],139.77544,35.67004,{"lat":89,"lon":88},[92],{"name":51,"role":31,"phone":93,"phoneExt":23,"email":23},"+81-3-3542-2511",{"type":95,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100640684","phase-1-clinical-study-of-mk-4884-in-participants-with-advanced-or-metastatic-solid-tumors-mk-4884-001-100640684",false,"NCT07600749","Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)","A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and\u002For advanced (metastatic) solid tumors:\n* Colorectal carcinoma (CRC)\n* Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and\u002For rhabdoid features)\n* Nonsquamous non-small cell lung cancer (NSCLC)\n* Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC)\n* Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1)\n* Has adequate organ function\n* Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\n* Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug\n* Has a history of clinically significant cardiac, cardiovascular and\u002For cerebrovascular disease\n* Has a serious nonhealing wound, ulcer, or bone fracture\n* Has an active infection(s) requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has a history of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery","ALL","18 Years",{"count":106,"type":107},120,"ESTIMATED","INTERVENTIONAL",[110],"PHASE1","Researchers are looking for new ways to treat certain types of advanced and\u002For metastatic solid tumors.\n\nThe main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.",[113],"Malignant Neoplasm","2026-06-25",{"date":116,"type":117},"2026-06-29","ACTUAL",{"date":119,"type":117},"2026-06-18",{"date":121,"type":107},"2029-10-04",{"name":5,"class":6},4]